Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CHKA | P35790 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205470 | 0.97 | KDM4E (0.60) | SIGMAR1HRH3KDM4EMEN1KMT2A | |
| SCHEMBL24317312 | 0.93 | KDM4E (0.60) | SIGMAR1HRH3KDM4EMEN1KMT2A | |
| SCHEMBL14407770 | 0.89 | SIGMAR1 (0.69) | SIGMAR1HRH3KDM4EMEN1KMT2A | |
| SCHEMBL278653 | 0.89 | SIGMAR1 (0.69) | SIGMAR1HRH3KDM4EMEN1KMT2A | |
| SCHEMBL2228267 | 0.84 | SIGMAR1 (0.81) | SIGMAR1HRH3MC4RLMNAPOLB | |
| SCHEMBL1045330 | 0.84 | SIGMAR1 (0.81) | SIGMAR1HRH3MC4RLMNAPOLB | |
| SCHEMBL329650 | 0.84 | SIGMAR1 (0.81) | SIGMAR1HRH3MC4RLMNAPOLB | |
| SCHEMBL7803337 | 0.84 | NPC1 (0.66) | HRH3KDM4EMEN1KMT2A | |
| SCHEMBL1044952 | 0.82 | SIGMAR1 (0.86) | SIGMAR1HRH3KMT2AMC4RLMNA | |
| SCHEMBL576379 | 0.82 | SIGMAR1 (0.86) | SIGMAR1HRH3KMT2AMC4RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | SIGMAR1 3709/4885HRH3 2551/4885KDM4E 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.